Valvular & structural heart disease
Antithrombotic therapy in patients after transcatheter aortic valve implantation: a network meta-analysis
Authors' conclusion
In post-TAVI patients, SAPT may provide the optimal balance of reducing thrombotic events while minimizing the risk of bleeding.
Study context
- Population
- Patients after transcatheter aortic valve implantation (TAVI) (median age 81 years; 3 trials enrolled patients with an oral anticoagulant (OAC) indication)
- Participants
- 6,415 patients11 randomized controlled trials (RCTs)
- Comparison
- OAC and antiplatelet regimens after TAVI
- Outcome
- Co-primary: all-cause death and major bleeding
- Follow-up
- Median 6 months
Methodological detailsrandom-effects model with informative priors, includes 1 unpublished RCT, Overall risk of bias low or with some concerns
- Random-effects model with informative priors
- Includes 1 unpublished RCT
- Overall risk of bias low or with some concerns
Pooled result
As reported in the abstract
Odds ratio (95% CrI)
OAC + SAPTvs DAPTall-cause death; 95% credible interval
1.78(1.15–2.77)
- Single antiplatelet therapy (SAPT) vs dual antiplatelet therapy (DAPT), direct-acting OAC, OAC + SAPT · major bleeding; reduced risk
- OR 0.20-0.40
Original publication
Antithrombotic therapy in patients after transcatheter aortic valve implantation: a network meta-analysis. Eur Heart J Cardiovasc Pharmacother. Published 11 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →